A stage 4 pancreatic cancer diagnosis marks metastatic disease, requiring specialized treatment strategies that balance life extension with quality of life. Modern protocols combine chemotherapy, targeted therapy, immunotherapy, and integrated supportive care to manage symptoms and slow progression. Key Takeaways Stage 4 pancreatic cancer treatment is palliative, not curative, focusing on extending survival and maintaining quality of life through systemic therapies and suppor

Stage 4 pancreatic cancer treatment options have evolved significantly beyond chemotherapy alone, with personalized approaches now guiding decisions based on tumor biology, genetic markers, performance status, and patient goals rather than one-size-fits-all protocols. TL;DR Only 15 to 20% of pancreatic cancers are diagnosed at a potentially resectable stage, making stage 4 treatment focused on extending life, managing symptoms, and maintaining quality of life [1] FOLFIRINOX a

TL;DR Stage 4 pancreatic cancer treatment primarily involves systemic chemotherapy, with FOLFIRINOX achieving median survival of 11 months and gemcitabine/nab-paclitaxel regimens reaching 8.5 months [3] Only 49.1% of stage 4 pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and comorbidity scores [4] Targeted therapies including PARP inhibitors for BRCA mutations, NTRK inhibitors, and KRAS inhibitors provide pers